---
title: "SHENGDA BIO-PHARM released its first-quarter performance, with a net profit attributable to the parent company of 21.7095 million yuan, a year-on-year increase of 469.35%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237690493.md"
description: "SHENGDA BIO-PHARM released its Q1 2025 performance report, with operating revenue of 203 million yuan, a year-on-year increase of 9.95%. The net profit attributable to the parent company was 21.7095 million yuan, a year-on-year increase of 469.35%; the net profit after deducting non-recurring gains and losses was 19.7178 million yuan, a year-on-year increase of 1749.87%. The basic earnings per share were 0.13 yuan/share"
datetime: "2025-04-27T08:04:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237690493.md)
  - [en](https://longbridge.com/en/news/237690493.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237690493.md)
generator: "portal-rs"
---

# SHENGDA BIO-PHARM released its first-quarter performance, with a net profit attributable to the parent company of 21.7095 million yuan, a year-on-year increase of 469.35%

According to the Zhitong Finance APP, SHENGDA BIO-PHARM (603079.SH) released its first-quarter report for 2025, with the company's first-quarter operating income of 203 million yuan, a year-on-year increase of 9.95%; net profit attributable to shareholders of the listed company was 21.7095 million yuan, a year-on-year increase of 469.35%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 19.7178 million yuan, a year-on-year increase of 1749.87%; basic earnings per share were 0.13 yuan/share

### Related Stocks

- [603079.CN](https://longbridge.com/en/quote/603079.CN.md)

## Related News & Research

- [RemeGen files board, board committee member list with disclosure responsibilities](https://longbridge.com/en/news/296803857.md)
- [12:30 ETAPLA HEALTH'S 42ND ANNUAL AIDS WALK LOS ANGELES RETURNS TO WEST HOLLYWOOD ON OCTOBER 18, 2026](https://longbridge.com/en/news/296940018.md)
- [AcuCort says Zeqmelit oral film wins 69% patient preference in real-world study](https://longbridge.com/en/news/296994929.md)
- [Tintina Mines appoints Claude Dufresne CEO, names Chris Stackhouse CFO](https://longbridge.com/en/news/296914981.md)
- [17:00 ETCulture Amp Adds Missing Context to AI, Infusing Culture Intelligence Directly Inside the Tools Leaders Use Daily](https://longbridge.com/en/news/296828906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**